search
Back to results

Oxcarbazepine Versus Placebo in Childhood Autism

Primary Purpose

Autism

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Oxcarbazepine
Placebo/sugar pill
Sponsored by
University of Medicine and Dentistry of New Jersey
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Autism focused on measuring Irritability, Functional Ability, Aggression, Mood Instability

Eligibility Criteria

5 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject has autism.
  • Subject is between five and seventeen years of age
  • Subject is not hospitalized.

Exclusion Criteria:

  • Subject has been diagnosed with a psychopathic disorder or a mood disorder, including depression or bipolar disorder.
  • Subject has displayed self-injurious behavior.
  • Subject has an active seizure disorder or epilepsy.
  • Subject has an unstable medical illness.
  • Subject has undergone brain injury.
  • Subject has a history of diabetes.
  • Subject has a history of prior treatment with oxcarbazepine of 600 mg/day for 6 weeks.
  • Subject has used other study drugs within the previous 30 days.
  • Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.

Sites / Locations

  • Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Oxcarbazepine

Sugar Pill

Arm Description

Oxcarbazepine is the active drug to be given to subjects in the experimental arm

Patients are given either active or inactive intervention.

Outcomes

Primary Outcome Measures

Vineland Adaptive Behavior Scales
The Vineland Scale is a semi-structured informant interview that assesses subjects' functioning. It is administered to a caretaker/family member. The scale has been revised and standardized in all populations. This scale has been found to assess social deficits in autism and strengths in daily living skills. Items are classified under four major adaptive domains: communication, daily living skills, socialization and motor skills. The items are scored 0-2 (yes/sometimes/never). Each domain is summed, and the domain scores are converted to standardized scores. The normative score is 100, with standard deviation of 15. The standardized score is used in this study. A higher score (above 100) means better adaptive behavior. Minimum value is 0, maximum value is infinity.
Aberrant Behavior Checklist
Aberrant Behavior Checklist (ABC)-Community Version (Irritability Subscale) (Aman et al. 1985). It is designed to objectively identify five behavior subscales through observation by the primary caregiver. The five behavior subscales include (ranges show no problem to severe problem): irritability (range 0-45), lethargy (range 0-48), stereotypy (range 0-21), hyperactivity range 0-48), and inappropriate speech (range 0-12), all possible signs and symptoms of affective instability in autistic individuals (Lainhart & Folstein, 1994). Improvement is shown with scores decreasing over time. Total score is not used. Inter-rater reliability for the ABC-CV is moderate to high across subscales with a mean of .63. Test-retest reliability correlations are .98 -Irritability, .99 -Lethargy, .98 -Stereotypy, .98 -Hyperactivity, and .96 -Inappropriate Speech. The ABC will be filled out by an informant (teacher/parent), and then reviewed by the IE. Administration time is approximately 10 minutes.
Autism Diagnostic Observation Schedule
The Autism Diagnostic Observation Schedule is primarily used as a diagnostic tool providing a standardized assessment for observation of social and communicative behavior in children and adults. It is composed of four modules for assessing children/adults of varying language ability (Module 1 for nonverbal individuals, to Module 4 fluent individuals). The instrument provides a series of structured and semi-structured presses for social interaction and communication, which are then scored. The scores are 0 (no behavior) to 3 (markedly abnormal). Subcategories are Language/communication, 8 scores, Social interaction, 12 scores, Stereotyped Behavior/restricted interests, 4 scores and Play, 2 scores, as well as other behavior, 3 scores. The maximum score is 87, minimum is 0, with cutoff scores to determine diagnosis. Higher scores indicate a more severe behavioral disorder.
Clinical Global Impression Improvement (CGI-AD)
Clinical Global Impression Improvement (CGI)-AD (Guy, 1976). This is a standard rating scale with 7-point global severity and change scales which has been modified for Autistic Disorder. A rating of 2 is given when there is a substantial reduction in symptoms so that a treating clinician would be unlikely to change treatment. A rating of 1 is reserved for patients who become virtually symptom-free. A rating of 3 (minimally improved) on the CGI is defined as slight symptomatic improvement that is not deemed clinically significant. Administration time is approximately 2 minutes.

Secondary Outcome Measures

Full Information

First Posted
April 27, 2007
Last Updated
January 7, 2021
Sponsor
University of Medicine and Dentistry of New Jersey
Collaborators
National Alliance for Research on Schizophrenia and Depression
search

1. Study Identification

Unique Protocol Identification Number
NCT00467753
Brief Title
Oxcarbazepine Versus Placebo in Childhood Autism
Official Title
Oxcarbazepine Versus Placebo in Childhood Autism
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
April 2006 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Medicine and Dentistry of New Jersey
Collaborators
National Alliance for Research on Schizophrenia and Depression

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism.
Detailed Description
The proposed study is designed to assess the effectiveness of treatment with Oxcarbazepine vs. placebo in childhood/adolescent autism. This is a twelve-week study involving twenty subjects between the ages of five and seventeen with a diagnosis of autism. Subjects will receive a psychiatric and medical evaluation by the study psychiatrist to see if she/he has any psychiatric or medical illnesses that would interfere with their ability to participate in this study. These evaluations may take up to an hour to complete. In addition, subjects will be asked to participate in a psychiatric interview designed to determine the child's diagnosis and current problem areas. The subject's parent will also be asked to fill out psychiatric questionnaires. The interview and questionnaires may take up to 4 hours to complete.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autism
Keywords
Irritability, Functional Ability, Aggression, Mood Instability

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oxcarbazepine
Arm Type
Experimental
Arm Description
Oxcarbazepine is the active drug to be given to subjects in the experimental arm
Arm Title
Sugar Pill
Arm Type
Placebo Comparator
Arm Description
Patients are given either active or inactive intervention.
Intervention Type
Drug
Intervention Name(s)
Oxcarbazepine
Other Intervention Name(s)
Trileptal
Intervention Description
Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
Intervention Type
Other
Intervention Name(s)
Placebo/sugar pill
Intervention Description
Dosage similar to active drug
Primary Outcome Measure Information:
Title
Vineland Adaptive Behavior Scales
Description
The Vineland Scale is a semi-structured informant interview that assesses subjects' functioning. It is administered to a caretaker/family member. The scale has been revised and standardized in all populations. This scale has been found to assess social deficits in autism and strengths in daily living skills. Items are classified under four major adaptive domains: communication, daily living skills, socialization and motor skills. The items are scored 0-2 (yes/sometimes/never). Each domain is summed, and the domain scores are converted to standardized scores. The normative score is 100, with standard deviation of 15. The standardized score is used in this study. A higher score (above 100) means better adaptive behavior. Minimum value is 0, maximum value is infinity.
Time Frame
Evaluated during Baseline and Termination
Title
Aberrant Behavior Checklist
Description
Aberrant Behavior Checklist (ABC)-Community Version (Irritability Subscale) (Aman et al. 1985). It is designed to objectively identify five behavior subscales through observation by the primary caregiver. The five behavior subscales include (ranges show no problem to severe problem): irritability (range 0-45), lethargy (range 0-48), stereotypy (range 0-21), hyperactivity range 0-48), and inappropriate speech (range 0-12), all possible signs and symptoms of affective instability in autistic individuals (Lainhart & Folstein, 1994). Improvement is shown with scores decreasing over time. Total score is not used. Inter-rater reliability for the ABC-CV is moderate to high across subscales with a mean of .63. Test-retest reliability correlations are .98 -Irritability, .99 -Lethargy, .98 -Stereotypy, .98 -Hyperactivity, and .96 -Inappropriate Speech. The ABC will be filled out by an informant (teacher/parent), and then reviewed by the IE. Administration time is approximately 10 minutes.
Time Frame
Bi weekly
Title
Autism Diagnostic Observation Schedule
Description
The Autism Diagnostic Observation Schedule is primarily used as a diagnostic tool providing a standardized assessment for observation of social and communicative behavior in children and adults. It is composed of four modules for assessing children/adults of varying language ability (Module 1 for nonverbal individuals, to Module 4 fluent individuals). The instrument provides a series of structured and semi-structured presses for social interaction and communication, which are then scored. The scores are 0 (no behavior) to 3 (markedly abnormal). Subcategories are Language/communication, 8 scores, Social interaction, 12 scores, Stereotyped Behavior/restricted interests, 4 scores and Play, 2 scores, as well as other behavior, 3 scores. The maximum score is 87, minimum is 0, with cutoff scores to determine diagnosis. Higher scores indicate a more severe behavioral disorder.
Time Frame
Evaluated during Baseline and Termination
Title
Clinical Global Impression Improvement (CGI-AD)
Description
Clinical Global Impression Improvement (CGI)-AD (Guy, 1976). This is a standard rating scale with 7-point global severity and change scales which has been modified for Autistic Disorder. A rating of 2 is given when there is a substantial reduction in symptoms so that a treating clinician would be unlikely to change treatment. A rating of 1 is reserved for patients who become virtually symptom-free. A rating of 3 (minimally improved) on the CGI is defined as slight symptomatic improvement that is not deemed clinically significant. Administration time is approximately 2 minutes.
Time Frame
Administered weekly Administered weekly

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has autism. Subject is between five and seventeen years of age Subject is not hospitalized. Exclusion Criteria: Subject has been diagnosed with a psychopathic disorder or a mood disorder, including depression or bipolar disorder. Subject has displayed self-injurious behavior. Subject has an active seizure disorder or epilepsy. Subject has an unstable medical illness. Subject has undergone brain injury. Subject has a history of diabetes. Subject has a history of prior treatment with oxcarbazepine of 600 mg/day for 6 weeks. Subject has used other study drugs within the previous 30 days. Subject is a pregnant female or unwilling to use acceptable contraception if sexually active.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sherie L. Novotny, M.D
Organizational Affiliation
University of Medicine and Dentistry of New Jersey
Official's Role
Principal Investigator
Facility Information:
Facility Name
Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS
City
Piscataway
State/Province
New Jersey
ZIP/Postal Code
08854
Country
United States

12. IPD Sharing Statement

Links:
URL
http://ubhc.umdnj.edu
Description
University Behavioral Healthcare official site

Learn more about this trial

Oxcarbazepine Versus Placebo in Childhood Autism

We'll reach out to this number within 24 hrs